NewEdge Advisors’s Myriad Genetics MYGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-52,385
Closed -$299K – 4372
2026
Q2
$299K Buy
+52,385
New +$238K ﹤0.01% 2494
2021
Q4
– Sell
-8,882
Closed -$287K – 1677
2021
Q3
$287K Buy
8,882
+334
+4% +$11.1K 0.01% 917
2021
Q2
$261K Buy
+8,548
New +$247K 0.01% 962

Other funds holding MYGN

NewEdge Advisors's MYGN Position: Q3 2026 in Review

NewEdge Advisors sold out of Myriad Genetics (MYGN) in Q3 2026, closing a stake of 52,385 shares — an estimated $299K sold.

NewEdge Advisors first reported a position in MYGN in Q2 2021 and held it in 3 quarters. The position peaked at $299K in Q2 2026. 176 funds tracked by Wall St. Rank hold MYGN as of Q3 2026.

  • NewEdge Advisors reported no remaining Myriad Genetics position as of Q3 2026 after selling out during the quarter.
  • NewEdge Advisors sold 52,385 Myriad Genetics shares in Q3 2026, an estimated $299K.
  • NewEdge Advisors first reported a position in Myriad Genetics in Q2 2021 and held it in 3 quarters.
  • NewEdge Advisors's Myriad Genetics position peaked at $299K in Q2 2026.
  • 176 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2026.

Based on NewEdge Advisors's 13F filing for Q3 2026, filed 13 Nov 2026.